Fatal Heart Failure Induced by Pazopanib in a Sarcoma Patient Previously Treated with Gemcitabine

© 2020 Saudi Heart Association.

Bibliographische Detailangaben
Veröffentlicht in:Journal of the Saudi Heart Association. - 1999. - 32(2020), 2 vom: 09., Seite 285-287
1. Verfasser: Di Lisi, Daniela (VerfasserIn)
Weitere Verfasser: Manno, Girolamo, Filorizzo, Clarissa, Guarino, Tommaso, Santanelli, Giulia, Lunetta, Monica, Badalamenti, Giuseppe, Russo, Antonio, Novo, Giuseppina
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Journal of the Saudi Heart Association
Schlagworte:Case Reports cardio-oncology cardiotoxicity gemcitabine heart failure pazopanib
LEADER 01000naa a22002652 4500
001 NLM317230530
003 DE-627
005 20231225162813.0
007 cr uuu---uuuuu
008 231225s2020 xx |||||o 00| ||eng c
024 7 |a 10.37616/2212-5043.1125  |2 doi 
028 5 2 |a pubmed24n1057.xml 
035 |a (DE-627)NLM317230530 
035 |a (NLM)33154930 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Di Lisi, Daniela  |e verfasserin  |4 aut 
245 1 0 |a Fatal Heart Failure Induced by Pazopanib in a Sarcoma Patient Previously Treated with Gemcitabine 
264 1 |c 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Revised 07.11.2020 
500 |a published: Electronic-eCollection 
500 |a Citation Status PubMed-not-MEDLINE 
520 |a © 2020 Saudi Heart Association. 
520 |a Gemcitabine is commonly used for various solid organ malignancies with rarely reported cardiac side effects such as cardiomyopathy. Pazopanib usually can cause arterial hypertension but cases of heart failure have recently been reported. We describe a case of fatal heart failure after treatment with gemcitabine and pazopanib in a 55-year-old female with sarcoma. Patient developed left ventricular dysfunction after gemcitabine treatment and acute heart failure after 22 days of pazopanib treatment which led to death. Physicians should be aware of the cardiotoxicity risk when managing the use of pazopanib especially in patients previously treated with other cardiotoxic drugs 
650 4 |a Case Reports 
650 4 |a cardio-oncology 
650 4 |a cardiotoxicity 
650 4 |a gemcitabine 
650 4 |a heart failure 
650 4 |a pazopanib 
700 1 |a Manno, Girolamo  |e verfasserin  |4 aut 
700 1 |a Filorizzo, Clarissa  |e verfasserin  |4 aut 
700 1 |a Guarino, Tommaso  |e verfasserin  |4 aut 
700 1 |a Santanelli, Giulia  |e verfasserin  |4 aut 
700 1 |a Lunetta, Monica  |e verfasserin  |4 aut 
700 1 |a Badalamenti, Giuseppe  |e verfasserin  |4 aut 
700 1 |a Russo, Antonio  |e verfasserin  |4 aut 
700 1 |a Novo, Giuseppina  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Journal of the Saudi Heart Association  |d 1999  |g 32(2020), 2 vom: 09., Seite 285-287  |w (DE-627)NLM098225227  |x 1016-7315  |7 nnns 
773 1 8 |g volume:32  |g year:2020  |g number:2  |g day:09  |g pages:285-287 
856 4 0 |u http://dx.doi.org/10.37616/2212-5043.1125  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 32  |j 2020  |e 2  |b 09  |h 285-287